Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 101, 1996, Pages 3-8

  Morrison, David C ^a,b   Bucklin, Scott E ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CEFTAZIDIME; CYCLOPHOSPHAMIDE; ENDOTOXIN; GALACTOSAMINE; IMIPENEM; INTERLEUKIN 6; MEROPENEM; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HUMORAL IMMUNITY; LETHALITY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PATHOGENESIS; PSEUDOMONAS; SEPSIS; ANIMAL; REVIEW; SECRETION;

ANIMALS; ANTI-BACTERIAL AGENTS; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICE; SEPSIS;

EID: 0030300199     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307: 1225-1230, 1982.
2. Morrison DC, Danner RL, Dinarello CA et al. Bacterial endotoxins and pathogenesis of Gram-negative infections: current status and future direction. J Endotoxin Res 1: 71-83, 1994.
3. Morrison DC, Ulevitch RJ. A review - the interaction of bacterial endotoxins with cellular and humoral mediation systems. Am J Path 92: 527-618, 1978.
4. Rietschel ETh, Brade H. Bacterial endotoxins. Sci Am 267: 54-61, 1992.
5. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. In: Creger WP, ed. Annual Rev. Medicine. Palo Alto, CA: Ann. Reviews Inc., 417-432, 1987.
6. Appelmelk BJ, Cohen J. The protective role of antibodies to the lipopolysaccharide core region. In: Ryan JL, Morrison DC, eds. Bacterial Endotoxic Lipopolysaccharides, Volume II Immunopharmacology and Pathophysiology. Boca Raton, FL: CRC Press, 376-410, 1992.
7. Cross AS, Opal S. Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? J Endotoxin Res 1: 57-69, 1994.
8. Morrison DC, Ryan JL, eds. Novel Therapeutic Strategies in the Treatment of Sepsis. Marcel Dekker Inc., New York, NY, 1995.
9. Ammons WS, Mallari C. An N-terminal fragment of bactericidal/permeability-inereasing protein protects against hemodynamic and metabolic derangements in rat Gram-negative sepsis. J Endotoxin Res 3: 57-66, 1996.
10. Kirikae T, Lei M-G, Chen T, Morrison DC. Interactions of endotoxins with membranes and membrane receptors. In: Brigham KL, ed. Endotoxin and the Lungs. New York: Marcel Dekker, 21-44, 1994.
11. Leeson MC, Morrison DC. Induction of proinflammatory responses in human monocytes by particulate and soluble forms of lipopolysaccharide. Shock 2: 235-245, 1994.
12. Tesh VL, Morrison DC. The interaction of E. coli with normal human serum: factors affecting the capacity of serum to mediate lipopolysaccharide release. Microb Pathog 4: 175-187, 1988.
13. Duncan RL Jr, Hoffman J, Tesh VL, Morrison DC. Immunological activity of lipopolysaccharides released from macrophages after the uptake of intact E. coli in vitro. J Immunol 136: 2924-2929, 1986.
14. Prins JM, van Deventer SJH, Kuijper EJ, Speelman P. Clinical relevance of antibiotic induced endotoxin release. Minireview. Antimicrob Agents Chemother 38: 1211-1218, 1994.
15. Hurley JC. Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis 15: 840-854, 1992.
16. Spink WW, Hall WH, Shaffer JM, Braude AI. Human brucellosis: its specific treatment with a combination of streptomycin and sulfadizine. JAMA 136: 382, 1948.
17. Russo-Marie F. Rationale for intervention strategies in sepsis: practical realities. In: Gram-Negative Infections and Sepsis: from Basic Concepts to Clinical Chemotherapy. Whitehouse Station NJ: Merck & Co Inc, 7-10, 1995.
18. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 76: 5939-5943, 1970.
19. Bucklin SE, Silverstein R, Morrison DC. An II-6 induced acute phase response does not confer protection against lipopolysaccharide lethality. Infect Immun 61: 3184-3189, 1993.
20. Bucklin SE, Morrison DC. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of Gramnegative sepsis. J Infect Dis 172: 1519-1527, 1995.
21. Bucklin SE, Lake P, Logdberg L, Morrison DC. Therapeutic efficacy of a polymysin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agents Chemother 39: 1462-1466, 1995.
22. Jackson JJ, Kropp H. β-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of pencillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1033-1041, 1992.
23. Jackson JJ, Kropp H. Endotoxin liberation: influence on in vivo beta-lactam antibiotic efficacy. In: Morrison DC, ed. Gram-Negative Infections and Sepsis: from Basic Concepts to Clinical Chemotherapy. Whitehouse Station, NJ: Merck & Co Inc, 11-17, 1995.
24. Arditi M, Kabat W, Yogev R. Antibiotic-induced bacterial killing stimulates tumor necrosis factor-α release in whole blood. J Infect Dis 167: 240-244, 1993.
25. Prins JM, van Agtmael MA, Kuijper EJ, van Deventer SJH, Speelman P. Antibiotic-induced endotoxin release in patients with Gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J Infect Dis 172: 886-891, 1995.